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Preface
P R E F A C E 1
Since the Roe v Wade decision legalizing
abortion in 1973, perhaps no goal had been
more eagerly anticipated by the abortion
rights movement in the United States than
the availability of mifepristone, commonly
known as “RU-486,” or the “French abortion
pill.” Approved for use in France in
1988–with the French Minister of Health’s
famous assertion that the pill was the “moral
property” of French women,1–the campaign
to bring the drug to the U.S. took another
twelve years, given the inevitable entangle-
ment in domestic antiabortion politics. Now,
two years since the FDA’s final approval in
September 2000, clearly the fondest hopes of
the prochoice movement for this drug–that it
would dramatically increase the number of
new abortion providers, and spread access to
historically underserved areas–have not yet
occurred. (Nor for that matter, have the dire
predictions of the antiabortion movement
come to pass: that this drug was dangerous,
would be dispensed by untrained physi-
cians, and would result in numerous injuries
and deaths from uncontrolled bleeding).
Rather what has transpired since September
2000 is a widespread educational effort
about medical abortion within various sec-
tors of the medical community. Groups such
as the National Abortion Federation (NAF)
and Planned Parenthood Federation of
America, whose clinics provide the majority
of abortions performed in the United States,
have intensified their ongoing efforts to
introduce their membership to regimens gov-
erning mifepristone use, as well as another
form of medical abortion involving the drug
methotrexate, a cancer drug that has for
some time been used for the “off-label” pur-
pose of pregnancy termination. Additionally,
NAF and other prochoice medical groups
such as Physicians for Reproductive Choice
and Health, the American Women’s Medical
Association and the Association of
Reproductive Health professionals have
formed a consortium–the Medical Abortion
Education Project–whose purpose is to bring
awareness of these new regimens to medical
circles beyond the quite small world of
existing abortion providers. 
But these intensive educational efforts
within the medical community have not yet
been matched by similar efforts oriented
toward the general public or policy makers.
Many Americans still remain confused
between the “abortion pill” (mifepristone)
and “the morning after pill” (emergency
contraception). The latter, if used within 72
hours of unprotected intercourse, can pre-
vent a pregnancy from occurring; it cannot
terminate a pregnancy already established.
Many legislators and policymakers, more-
over–even those who are supporters of
abortion rights–are not aware of the various
regulatory and bureaucratic barriers that
must be overcome to achieve the previously
mentioned goals of raising the numbers of
“new” abortion providers, that is those who
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are not currently providers of surgical abor-
tion, and bringing abortion provision to
some of those 85% of U.S. counties current-
ly without such services.2
Understaning Medical Abortion is thus a
particularly welcome addition to the litera-
ture on medical abortion. In impressively
clear and straightforward terms, the authors
review the history of FDA approval of
mifepristone in the U.S., explain the med-
ical regimens involved in both mifepristone
and methotrexate abortions, debunk the
misinformation spread by antiabortion
forces about the safety of these regimens,
offer an overview of the current status of
abortion provision in this country, and
demonstrate the promise of medical abor-
tion to improve an unacceptably low level
of access for many American women. Most
importantly, however, this monograph out-
lines the numerous challenges that exist for
those health care providers who wish to
begin to offer this service, and offers a num-
ber of excellent recommendations to over-
come these obstacles.
Reading Understanding Medical Abortion
makes clear that these new regimens, like
surgical abortion, are, medically speaking,
relatively simple procedures with a very
high degree of efficacy and safety. But politi-
cally speaking, there is no area of medicine
in the United States that is more scrutinized
and more regulated than abortion services.
As a colleague and I have recently written,
the struggle to integrate mifepristone into
mainstream medical circles in the U.S. is
one of attempting to “normalize the excep-
tional.”3 To put this issue in perspective,
however, we can learn much from an impor-
tant recent report on the experience of
mifepristone in Europe.4 Reporting on
France, Great Britain, and Sweden, the
authors note that in those countries–in a
political environment far less divided about
abortion than our own–it took a full decade
for mifepristone provision to take hold with-
in medical establishments. Most important-
ly, though, in the European context mifepris-
tone has started to live up to one of its major
public health promises–since the introduc-
tion of this drug, a higher proportion of all
abortions in each country are now taking
place earlier in pregnancy. In spite of the
unique challenges abortion services face in
the United States, we can be optimistic that
in the long run, medical abortion will have a
similar impact here–and the intelligent
analysis and wise recommendations offered
by Understanding Medical Abortion will
surely contribute to this effort.
Carole Joffe, Ph.D.
Professor of Sociology, 
University of California, Davis, 
and Adjunct Professor of Obstetrics 
and Gynecology, 
University of California, San Francisco.
P R E F A C E2
Early medical abortion has the potential to
expand women’s access to abortion services
in the U.S. and provide women with a
choice of abortion methods. Mifepristone
and methotrexate, the two drugs most often
used in medical abortion, are safe and effec-
tive in terminating early pregnancies.
However, despite the attention given to the
approval of mifepristone (also known as RU-
486 and Mifeprex™) by the U.S. Food and
Drug Administration in 2000, many miscon-
ceptions and gaps in understanding about
medical abortion persist. 
This monograph synthesizes what is current-
ly known about medical abortion and pro-
vides an overview of the legal and political
issues that have shaped its practice in the
U.S. In order to address some of the needs of
new providers, organizations such as the
National Abortion Federation offer training
and other resources related to the practice of
medical abortion. However, people outside
the medical community, especially legisla-
tors, policymakers, and the media, also can
have a significant impact on the accessibility
and acceptability of medical abortion. This
monograph is intended for this latter group,
with the intention of increasing understand-
ing of medical abortion and providing infor-
mation and discussion useful in creating
policy that supports the provision of med-
ical abortion. Understanding Medical
Abortion: Policy, Politics, and Women’s
Health is shaped by the authors’ public
health background and belief that full repro-
ductive choice, including the freedom to
choose abortion for termination of an unin-
tended pregnancy, is essential to the health
and well-being of women.
The monograph is divided into five chap-
ters. The first chapter defines medical abor-
tion and provides information about mifepri-
stone and methotrexate. It includes the med-
ical regimens associated with both drugs.
The second chapter examines obstacles to
surgical abortion provision in the U.S. and
the potential of medical abortion to expand
access and increase options for women who
choose abortion. The third chapter addresses
the political and legal challenges to medical
abortion provision in the U.S., including
restrictive laws that may extend to medical
abortion. The fourth chapter addresses the
challenges that providers who offer medical
abortion may face. Based on the information
and discussion in the previous chapters, the
recommendations made in the final chapter
are aimed at removing obstacles to medical
abortion, improving women’s knowledge of
medical abortion regimens, and promoting
the diffusion of medical abortion practice in
the U.S. 
If current trends continue, 43% of women in
the United States will have had an abortion
by age 45.5 Although abortion services have
become highly politicized in the U.S., the
public health benefits of safe, legal abortion
3
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are clear. Since abortion was legalized, the
declines in abortion-related and pregnancy-
related deaths and disability among U.S.
women have been dramatic.6 We believe that
medical abortion, like abortion in general,
should be included in the full range of
reproductive health care services offered to
women. Besides giving women a choice of
methods, medical abortion may also allow
women to make pregnancy decisions earlier
than was the case previously.
We hope this monograph will contribute to
the understanding of medical abortion
among policymakers, legislators and the
media. Although this monograph focuses on
specific health care delivery and public pol-
icy changes, these changes must be
addressed within the larger context of
women in society. The reproductive health
needs of women are inextricably linked to
gender inequality, sexism, and racism, and
the increasing feminization of poverty.
Thus, long term solutions to improving the
health and well-being of women, men, and
families will require not only the implemen-
tation of changes such as those outlined in
this monograph, but also the active involve-
ment of public health professionals,
women’s health advocates, and health care
providers in political and social change.
Bringing medical abortion into the main-
stream of American medicine could
improve abortion practice in the U.S. and
enhance women’s health.
Medical abortion is the termination of early
pregnancy using a drug or combination of
drugs that are administered orally, intramus-
cularly, and/or vaginally, first causing the
pregnancy to terminate and then causing the
uterus to expel the products of conception.
In contrast to medical abortion, surgical
abortion involves inserting instruments
through the cervix into the uterus and
removing the products of conception. Below
we describe the two methods of medical
abortion available in the United States today. 
The 3 M’s: Mifepristone,
Methotrexate 
and Misoprostol
There are three medications used in the U.S.
for medical abortion: mifepristone (also
known as RU-486 or “the French abortion
pill”), methotrexate, and misoprostol.
Mifepristone (brand name Mifeprex™) is an
anti-progesterone that alters the uterine lin-
ing and disrupts attachment of a fertilized
egg. Mifepristone has been approved by the
U.S. Food and Drug Administration (FDA)
for medical abortion. Methotrexate (brand
name Folex®), an anti-metabolite, stops cell
division in the developing placenta thereby
interfering with cell growth and further
attachment to the uterine lining.7, 8
Methotrexate was approved by the FDA in
1953 and has been used in the treatment of
cancer, severe psoriasis, severe arthritis, and
ectopic pregnancy. Both mifepristone and
methotrexate are most often used in con-
junction with a third medication, misopros-
tol. Misoprostol (brand name Cytotec®) is a
prostaglandin analogue which softens the
cervix and stimulates uterine contractions to
expel the products of conception.
Misoprostol has been approved by the FDA
for the treatment of ulcers and is commonly
used in labor induction to thin, relax, soften
and open the cervix.9, 10
S E C T I O N  I :  W H A T  I S  M E D I C A L  A B O R T I O N ? 5
What is 
Medical 
Abortion?
The use of methotrexate in medical abortion is
an off-label use. Off-label refers to the use of a
drug for a disease or condition other than the
indication for which it was approved by the
FDA. This does not mean that off-label use is
inherently risky, experimental, or novel. Off-label
use of drugs is an integral feature of medical
practice and often reflects approaches that
have been extensively reported in
medical literature. The American
Medical Association (AMA) esti-
mates that off-label uses account
for 40% to 60% of the prescrip-
tions written each year.*
Off-Label Use 
and Methotrexate
*Beck JM, Azari ED.
FDA, off-label use, and
informed consent:
Debunking myths and
misconceptions. Food
Drug Law J.
1998;53(1):71-104.
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What Do We Know About
Mifepristone (RU 486)?
History of Mifepristone 
and its Journey to the U.S.
Mifepistone was developed in 1981 by the
French pharmaceutical firm, Roussel-Uclaf.
Drug manufacturers in the U.S., however,
were reluctant to be involved in the produc-
tion and distribution of mifepristone because
anti-choice groups threatened consumer boy-
cotts.11 Therefore, despite overwhelming evi-
dence of the safety and
effectiveness* of
mifepristone for the
termination of early
pregnancy, the FDA
did not approve
mifepristone until
September, 2000. The
following time line
provides an overview
of key events in the journey from initial prod-
uct development to FDA approval.12-15
What is Mifepristone 
and How Does it Work? 
Mifepristone is a synthetic steroid that
blocks the action of progesterone, which is
necessary to maintain pregnancy. Blocking
the action of progesterone is believed to pro-
duce changes in the endometrium (uterine
lining), inducing menstrual bleeding and the
shedding of the uterine lining. In addition,
the drop in progesterone causes the cervix to
soften and uterine contractions to begin.16
Misoprostol is then administered to further
stimulate contractions, expelling the prod-
ucts of conception.
How is Mifepristone Administered?
The FDA specified a regimen at the time it
issued its approval of mifepristone.
However, other evidence-based regimens are
commonly used.
• FDA Regimen. The FDA-approved regi-
men requires three office visits – one for
administration of mifepristone, one for
administration of the prostaglandin
(misoprostol), and a final visit two weeks
after administration of mifepristone to
confirm completion of the abortion. The
regimen provides for medical abortion as
early as when a pregnancy can be con-
firmed, and was approved for use
through seven weeks, or 49 days, since
the last menstrual period (LMP).17
Step 1: Mifepristone administration –
The patient takes a single oral dose of
600 mg of mifepristone.
Step 2: Misoprostol administration – Two
days after taking the mifepristone, the
patient returns to the provider. If a com-
plete abortion has not yet occurred, the
patient takes a single oral dose of 400
mcg of misoprostol. 
Step 3: Post-treatment examination –
Approximately two weeks after adminis-
tration of mifepristone the patient returns
for a clinical or ultrasound exam to con-
firm that a complete abortion has
occurred. 
• Evidence-based Regimens. Research is
continuing on new regimens for medical
abortion. Many providers are using regi-
mens other than the FDA-specified regi-
men for medical abortion with equal or
greater effectiveness. For example, some
providers allow home administration of
misoprostol. These regimens differ in
mode of administration of the misopros-
tol, timing of administration, dose of
medications, and gestational age at which
mifepristone can be given.
S E C T I O N  I :  W H A T  I S  M E D I C A L  A B O R T I O N ?6
*The terms effectiveness and efficacy
are both used in presenting findings
from studies on medical abortion.
Efficacy usually refers to a drug’s
ability to produce the intended result
in a clinical trial. Effectiveness usual-
ly refers to a drug’s ability to pro-
duce the intended result in a real
world setting. Within this document,
we use effectiveness in reference to
both clinical and real world settings.
Mode of administration. Many studies
have demonstrated that vaginal adminis-
tration of misoprostol (as opposed to
oral) results in comparable or higher
rates of complete abortion, sustained
effectiveness at higher gestational ages,
lower incidence of gastrointestinal side
effects, and more rapid completion of the
abortion.18-21
Dose of medications. Although the FDA
regimen specifies 600 mg of mifepristone
and 400 mcg of misoprostol, studies have
shown comparable rates of effectiveness
with a lower dose of mifepristone (200
mg) and a higher dose of misoprostol
(e.g., 800 mcg).21-24
Gestational age of pregnancy. Studies
have shown mifepristone-induced abor-
tions can be successfully performed up to
56 days LMP with oral administration of
misoprostol, compared with the shorter
time frame specified by the FDA (up to
49 days LMP).23 Abortions can also be
successfully performed up to 63 days
LMP with vaginal administration of miso-
prostol.23, 25 
Timing of administration. Studies have
documented that misoprostol can be
administered anywhere from 24 hours to
72 hours after administration of mifepris-
tone up through a gestational age of 63
days or less.26, 27
How Long Does it Take? 
A few women using the FDA-approved
mifepristone/misoprostol regimen will
experience expulsion of the pregnancy prior
to the administration of misoprostol. More
than half will experience a complete abor-
tion within four hours of administration of
misoprostol, and 70% to 80% within 24
hours.22, 23, 26-29 Ninety-five to 97% of women
will have a complete abortion within two
weeks. However, for some women a com-
plete abortion may take three to four
weeks.22, 23, 26, 27, 29, 30 There are several treat-
ment options for women with an incom-
plete abortion, including continued observa-
tion, repeat administration of misoprostol,
and surgical completion. Several factors,
including the woman’s symptoms and her
preferences, will determine the course of
treatment for incomplete abortion. 
Is Mifepristone Safe?
• Mifepristone Has Been Used Safely by
Millions of Women Worldwide.
Mifepristone has been used safely by mil-
lions of women globally,31-35 including
thousands of women in the U.S.22, 23, 26, 27, 29
The most common side effects are bleed-
ing and cramping. Many women also
experience nausea, vomiting, or diarrhea.36
• Serious Side Effects Are Rare. Serious
complications following a mifepristone/
S E C T I O N  I :  W H A T  I S  M E D I C A L  A B O R T I O N ? 7
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misoprostol-induced abortion are
extremely rare; infection and surgical
intervention for serious medical compli-
cations have occurred in fewer than 1%
of women.21, 22, 26, 29, 36 A commonly report-
ed outcome of medical abortion is heavy
bleeding. However less than 1% of
women undergoing a mifepristone/miso-
prostol-induced abortion have required
blood transfusions22, 24, 27, 29 or surgical
intervention23, 27, 37 due to heavy bleeding.
Less than 0.2% of women have required
transfusions in three large clinical
trials.29, 35, 38
A small number of cases of serious
adverse events have been reported,39, 40
including ruptured ectopic pregnancy,
bacterial infection, and one case of
myocardial infarction. Two patient deaths
have occurred, one resulting from sys-
temic bacterial infection and one follow-
ing hemorrhage due to a ruptured ectopic
pregnancy; however, no causal relation-
ships have been established between
these events and the use of mifepris-
tone/misoprostol.39
Is Mifepristone Effective? 
Mifepristone with misoprostol is very effec-
tive for termination of early pregnancy. For
pregnancies of seven weeks or less, effective-
ness rates exceed 95%.22, 23 Effectiveness can
be slightly lower in pregnancies of longer
duration depending upon the regimen used,
but across many regimens the effectiveness
averages 85% or greater up to nine weeks
LMP.21 In the trial conducted in the U.S. by
the Population Council, effectiveness
reached 77% at 57-64 days LMP (approxi-
mately eight to nine weeks LMP). Studies
using vaginal administration of misoprostol
have achieved effectiveness rates up to 98%
and 99%.21, 23
Who May Provide Medical Abortions
Using Mifepristone?
Under FDA regulations, mifepristone
(Mifeprex™) is distributed only to licensed
physicians who submit a signed Prescriber’s
Agreement to the pharmaceutical distributor,
Danco Laboratories. The Prescriber’s
Agreement stipulates that mifepristone will
be provided by or under the supervision of a
physician who can accurately assess the
duration of pregnancy, diagnose ectopic
pregnancy, and provide surgical abortion in
cases of incomplete abortion or make
arrangements for referral to a provider of
surgical abortion. Some state laws allow
non- physician providers (e.g., certified
physician assistants, nurse practitioners)
who work under the supervision of a physi-
cian to dispense mifepristone.17 Providers
must also have women who are seeking a
medical abortion sign a Patient Agreement
form that describes the regimen, give them a
Medication Guide, and notify the distributor
of mifepristone of any adverse events. 
What Do We Know 
About Methotrexate?
History of Methotrexate 
Methotrexate has been available in the U. S.
since 1953 when it was approved by the
FDA for the treatment of cancer. Since 1982,
methotrexate also has been used to treat
ectopic pregnancy. Providers and researchers
began to investigate and use methotrexate
for medical abortion in the 1990s when they
became frustrated with the delays in bring-
ing mifepristone to the U.S.41, 42 This drug is
not approved by the FDA for early pregnan-
cy termination, but because it is available by
prescription, physicians may legally pre-
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We are pleased that you wish to become a
provider of Mifeprex* (Mifepristone) Tablets, 200
mg, which is indicated for the medical termination
of intrauterine pregnancy through 49 days from
the first day of the patient’s last menstrual period
(see full prescribing information). Prescribing
Information, Mifeprex Medication Guide and
PATIENT AGREEMENT forms will be provided
together with your order of Mifeprex. 
Prior to establishing your account and receiving
your first order, you must sign and return this let-
ter to the distributor, indicating that you have met
the qualifications outlined below and will observe
the guidelines outlined below. If you oversee
more than one office facility, you will need to list
each facility on your order form prior to shipping
the first order. 
By signing the reverse side, you acknowledge
receipt of the PRESCRIBER’S AGREEMENT
and agree that you meet these qualifications and
that you will follow these guidelines for use. You
also understand that if you do not follow these
guidelines, the distributor may discontinue distri-
bution of the drug to you. 
Under Federal law, Mifeprex must be provided by
or under the supervision of a physician who
meets the following qualifications:
• Ability to assess the duration of pregnancy
accurately. 
• Ability to diagnose ectopic pregnancies.
• Ability to provide surgical intervention in
cases of incomplete abortion or severe
bleeding, or have made plans to provide such
care through others, and are able to assure
patient access to medical facilities equipped
to provide blood transfusions and resuscita-
tion, if necessary. 
• Has read and understood the prescribing
information of Mifeprex. The prescribing infor-
mation is attached to this letter, and is also
available by calling our toll free number, 1-
877-4 Early Option (1-877-432-7596), or 
logging on to our website, www.earlyoption-
pill.com. 
In addition to these qualifications, you must pro-
vide Mifeprex in a manner consistent with the fol-
lowing guidelines.
• Under Federal law, each patient must be pro-
vided with a Medication Guide. You must fully
explain the procedure to each patient, pro-
vide her with a copy of the Medication Guide
and PATIENT AGREEMENT, give her an
opportunity to read and discuss them, obtain
her signature on the PATIENT AGREEMENT,
and sign it yourself. 
• The patient’s follow-up visit at approximately
14 days is very important to confirm that a
complete termination of pregnancy has
occurred and that there have been no com-
plications. You must notify Danco
Laboratories in writing as discussed in the
Package Insert under the heading DOSAGE
AND ADMINISTRATION in the event of an
on-going pregnancy which is not terminated
subsequent to the conclusion of the treat-
ment procedure. 
• While serious adverse events associated with
the use of Mifeprex are rare, you must report
any hospitalization, transfusion or other seri-
ous event to Danco Laboratories, identifying
the patient solely by package serial number
to ensure patient confidentiality. 
• Each package of Mifeprex has a serial num-
ber. As part of maintaining complete records
for each patient, you must record this serial
number in each patient’s record. 
Danco Laboratories, LLC
P.O. Box 4816
New York, NY 10185
1-877-4 Early Option (1-877-432-7596)
www.earlyoptionpill.com
Prescriber’s Agreement
MIFEPREXTM
(Mifepristone) Tablets, 200 mg
1. I have read the attached Medication Guide
for using Mifeprex and misoprostol to end my
pregnancy. 
2. I discussed the information with my health
care provider (provider). 
3. My provider answered all my questions and
told me about the risks and benefits of using
Mifeprex and misoprostol to end my pregnan-
cy. 
4. I believe I am no more than 49 days (7
weeks) pregnant. 
5. I understand that I will take Mifeprex in my
provider’s office. 
6. I understand that I will take misoprostol in my
provider’s office two days after I take
Mifeprex (Day 3). 
7. My provider gave me advice on what to do if I
develop heavy bleeding or need emergency
care due to the treatment. 
8. Bleeding and cramping do not mean that my
pregnancy has ended. Therefore, I must
return to my provider’s office in about 2
weeks (about Day 14) after I take Mifeprex to
be sure that my pregnancy has ended and
that I am well. 
9. I know that, in some cases, the treatment will
not work. This happens in about 5 to 8
women out of 100 who use this treatment.
10. I understand that if my pregnancy continues
after any part of the treatment, there is a
chance that there may be birth defects. If my
pregnancy continues after treatment with
Mifeprex and misoprostol, I will talk with my
provider about my choices, which may
include a surgical procedure to end my preg-
nancy. 
11. I understand that if the medicines I take do
not end my pregnancy and I decide to have a
surgical procedure to end my pregnancy, or if
I need a surgical procedure to stop bleeding,
my provider will do the procedure or refer me
to another provider who will. I have the
provider’s name, address and phone number.
12. I have my provider’s name, address and
phone number and know that I can call if I
have any questions or concerns.
13. I have decided to take Mifeprex and miso-
prostol to end my pregnancy and will follow
my provider’s advice about when to take
each drug and what to do in an emergency. 
14. I will do the following:
• return to my provider’s office in 2 days
(Day 3) to check if my pregnancy has
ended. My provider will give me misopros-
tol if I am still pregnant.
• return to my provider’s office about 14 days
after beginning treatment to be sure that my
pregnancy has ended and that I am well 
Patient Signature:___________________________
Patient Name (print): ________________________
Date: _____________________________________
The patient signed the PATIENT AGREEMENT in
my presence after I counseled her and answered
all her questions. I have given her the Medication
Guide for mifepristone.
Provider’s Signature: ________________________
Name of Provider print: ______________________
Date: _____________________________________
After the patient and the provider sign this
PATIENT AGREEMENT, give 1 copy to the
patient before she leaves the office and put 1
copy in her medical record. Give a copy of the
Medication Guide to the patient. 
Patient Agreement
MIFEPREXTM
(Mifepristone) Tablets, 200 mg
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scribe it for this use. Evidence supports its
safety and effectiveness for this purpose.
Besides being widely available, methotrexate
is relatively inexpensive, especially in the
injectable form.
What Is Methotrexate 
and How Does It Work? 
Methotrexate is an anti-metabolite that
inhibits DNA synthesis and interferes with
cell growth.7, 41, 43 As such, methotrexate stops
the process of fetal development.41
How Is Methotrexate Administered?
Methotrexate can be given by injection or
taken orally. As with mifepristone,
methotrexate is followed by the administra-
tion of misoprostol, which can be adminis-
tered either orally or vaginally but is most
commonly administered vaginally.21
Sources: Kahn JG, Becker BJ, MacIsaa L, et al. The effectiveness of medical abortion: A meta-analysis. Contraception. 2000;61:29-40;
Stewart FH, Wells ES, Flinn SK, Weitz TA. Early Medical Abortion: Issues for Practice. San Francisco, CA: University of California, San
Francisco, Center for Reproductive Health Research and Policy; 2000; US Food and Drug Administration. Mifepristone questions and
answers. Available at: http://fda.gov/cder/drug/infopage/mifepristone/mifepristone-qa.htm. Accessed January 15, 2001.
Flow Chart
Mifepristone
Step 1: 3 tablets of mifepris-
tone (600 mg) are taken as a
single oral dose.
Step 1: 200 mg of mifepris-
tone are taken as a single oral
dose.
Step 2: 2 days after taking the
mifepristone, the patient
returns to the provider for oral
administration of 400 mcg of
misoprostol
Step 2: 24-72 hours after tak-
ing mifepristone, patient takes
800 mcg of misoprostol orally
or vaginally, either in the clinic
or at home.
Step 3: 2 weeks after admin-
istration of mifepristone the
patient returns for follow up
examination to confirm by clin-
ical exam or ultrasound exam
that a complete abortion has
occurred. 
Step 3: Within 2 weeks after
administration of misoprostol,
the patient returns for a clini-
cal exam or ultrasound to con-
firm that a complete abortion
has occurred.
Methotrexate
Step 1: A dose of
methotrexate is given, either
orally (50 mg) or by injection
(50 mg/m2).
Step 2: 3-7 days after the
methotrexate is given, the
patient takes misoprostol (800
mcg), which may be given
orally or inserted vaginally.
Step 3: The patient returns
to the provider about 14
days after the methotrexate
dose; a clinical exam or ultra-
sound confirms that a com-
plete abortion has occurred.
FDA Regimen Evidence-Based
Regimen
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Methotrexate regimens vary in dosage, in
administration (i.e., methotrexate taken oral-
ly or by injection), and in the number of
days between methotrexate and misoprostol
administration.
Step 1: Methotrexate administration –
The patient is either given 50 mg/m2 of
methotrexate by injection or takes 50 mg
orally.
Step 2: Misoprostol administration – Three
to seven days after taking the methotrexate,
the patient returns to the provider. If a
complete abortion has not occurred, the
patient is given 800 mcg of misoprostol,
administered orally or vaginally. 
Step 3: Post-treatment examination
–Approximately two weeks after adminis-
tration of methotrexate the patient returns
for a clinical or ultrasound exam to con-
firm that a complete abortion has
occurred. This visit can occur earlier.
How Long Does it Take?
Few women expel the products of con-
ception prior to the administration of the
misoprostol. Fifty to 70% of women
experience a complete abortion within
24 hours of the administration of miso-
prostol, with some differences in rates
resulting from mode of administration of
methotrexate.21, 44 The percentage increas-
es in the 24 hours following a second
dose of misoprostol, with the cumulative
rate of complete abortion increasing to
75% of women.7, 44 By the end of two
weeks up to 83% of women experience a
complete abortion,44, 45 and, after 21 days,
rates of completed abortion exceed
90%.7, 44 Women who are found to have
an incomplete abortion at the post-treat-
ment examination may opt for surgical
abortion or may continue to wait.46 Some
women are willing to wait weeks for the
bleeding to stop, while others are not.
Surgical abortion is strongly recommend-
ed for those women who have an ongo-
Comparison Chart for Mifepristone and Methotrexate
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Mifepristone/Misoprostol Methotrexate/Misoprostol
What is it?
Blocks the progesterone hormone
needed to maintain pregnancy.
Stops process of implantation.
How is it used?
Both drugs are given orally, two
days apart, in the FDA-approved
regimen. 
Methotrexate is injected or taken
orally; misoprostol is taken orally or
vaginally 3-7 days later.
Effectiveness 92%-96% 85%-96%
Common side effects Bleeding and cramping Bleeding and cramping
Availability in the U.S. FDA approved for early abortion.
FDA approved for other uses.
Evidence-based use for early abor-
tion
ing pregnancy at the second week fol-
low-up visit.7, 41, 47
Is Methotrexate Safe?
• Methotrexate Has Been Used Safely in
the U. S. for Years. Methotrexate has
been used safely since the 1950s for can-
cer treatment and since the early 1980s
for ectopic pregnancy. There are substan-
tial data regarding the safety and effec-
tiveness of methotrexate for medical abor-
tion.48-56 When used at dosages indicated
for medical abortion, common side effects
of methotrexate include bleeding, cramp-
ing, and gastrointestinal problems such as
nausea, vomiting, and diarrhea. 
• Serious Side Effects Are Rare. When
methotrexate is used for medical abor-
tion, serious side effects occur in less
than 1% of patients.21, 41 Like mifepris-
tone/misoprostol induced abortion,
bleeding is a commonly reported side
effect. However, fewer than 1% of women
have required intervention for heavy
bleeding.50, 52, 53
Is Methotrexate Effective? 
Methotrexate with misoprostol is a very
effective method of early pregnancy termina-
tion. Similar to mifepristone, early (i.e., up to
49 days LMP) methotrexate-induced abor-
tions have effectiveness rates of greater than
90%.21 Methotrexate is also effective for abor-
tions after 49 days LMP.21, 44, 52 Although some
studies have shown slightly lower effective-
ness rates using methotrexate after seven
weeks LMP (e.g., 85%),21, 51, 52 this may be due
to differences between the regimens in tim-
ing of drug administration and the number of
doses of misoprostol given, in addition to
gestational age. Although the effectiveness of
methotrexate/misoprostol is comparable to
mifepristone/misoprostol, methotrexate-
induced abortion can take longer, ranging
from one to five weeks.7, 44, 51, 53, 57 
Who May Provide Medical Abortion
Using Methotrexate?
An individual provider’s ability to prescribe
methotrexate depends on the scope of his or
her practice and whether there are adminis-
trative rules or specific state laws that regu-
late the prescription of methotrexate for
abortion. Some states limit provision of
abortion to physicians, and the limits and
conditions of prescribing privileges (e.g.,
which drugs can be prescribed by which
types of providers – physicians, registered
nurse practitioners, certified physician assis-
tants, etc.) differ from state to state.
In summary, medical abortion is both safe
and effective. Medical abortion usually
involves a combination of drugs, either
mifepristone with misoprostol or methotrex-
ate with misoprostol. Although mifepristone
has been approved by the FDA specifically
for early pregnancy termination, methotrex-
ate is also used for medical abortion. In
addition to being safe and effective, medical
abortion has the potential to expand
women’s access to abortion services and give
those who prefer it an alternative to surgical
abortion. The potential of medical abortion
to expand access and increase options is dis-
cussed in the following chapter.
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Abortion is one of the most frequently per-
formed surgical procedures in the United
States; data show that 43% of women will
have an abortion by the time they are 45
years old.5 Many assume that the availability
of surgical abortion in the U.S. is sufficient to
meet the needs of women wishing to termi-
nate a pregnancy. However, despite the safety
and effectiveness of surgical abortion, many
women have difficulty accessing abortion
services. In addition, women need diverse
options in abortion methods that fit with the
circumstances of their individual lives. 
Medical abortion has the potential to expand
both women’s access to abortion services
and choice among abortion methods. Below
we address the obstacles of limited access
and limited options as they apply to conven-
tional, surgical abortion. We then consider
how medical abortion could overcome some
of these obstacles. 
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Why 
Medical Abortion 
and Why Now?
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Map of U.S. Providers
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> 90% of counties without an abortion provider
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Access to Abortion
The Obstacle: 
Access to Abortion is Limited
Many women in the U.S., especially those in
rural areas, live in counties with no abortion
provider. A decline in providers and other
factors that limit women’s access to abortion
are described below.
• The Number of Providers Trained in
Performing Surgical Abortion is Low.
Training in abortion procedures has
declined in part because fewer abortions
are performed in hospital settings where
the majority of residency training occurs.
Although the percentage of programs offer-
ing training increased after the
Accreditation Council for Graduate
Medical Education began requiring abor-
tion training as a part of OB/GYN residen-
cy training in 1996 (for residents and pro-
grams without moral or religious objec-
tions), a 1998 survey found only 46% of
programs made first trimester abortion
training a routine part of their program.
Only 26% of programs reported all their
residents received training. Although many
programs say they offer optional off-site
training in abortion procedures, the already
overloaded OB/GYN resident is unlikely to
take advantage of such an option.58
• Abortion Services are Distributed
Unevenly. In most states, over three- quar-
ters of counties do not have an abortion
provider, and the entire Midwestern U.S.
lacks providers in 90% or more of its
counties.2 As a result, access to abortion is
very limited for many women living in the
U.S. According to recent data, the highest
rates of abortion (number of abortions per
1,000 live births) are concentrated in the
western U.S. (California, 38 abortions per
1,000 live births) and along the East Coast
(Delaware, 30 per 1,000; New York, 35 per
1,000; Washington, D.C., 68 per 1,000).
Relatively lower rates of abortion (fewer
than 10 abortions per 1,000 live births)
occur in the Midwest and the South.59, 60
State abortion rates vary due to multiple
factors (e.g., differential rates of pregnancy,
differences in state laws), but the variation
is also likely due to differences in the
accessibility of abortion services. 
• Anti-abortion Harassment Impacts Use
of Abortion Services. Most abortions are
performed in specialty abortion clinics
where at least half of all patient visits are
for pregnancy termination services.60
These facilities are the most likely to be
targeted for anti-abortion harassment.
Women who feel intimidated or threat-
ened by anti-abortion harassment may be
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1985- 1990- 1995-
1989 1994 2000
Picketing 580 6921 37,790
Bomb threats 196 74 223
Vandalism 174 341 324
Hate mail/harassing calls 166 1641 7149
Invasion 145 100 22
Death threats 43 155 112
Assault & battery 40 37 25
Arson 37 60 39
Attempted bomb/arson 26 27 16
Burglary 15 14 29
Bombing 6 4 11
Murder 0 5 2
Attempted murder 0 11 6
Kidnapping 0 0 1
Stalking* — 210 222
*Tabulation of stalking incidents began in 1993
Incidents of Violence 
and Disrutpion Against
Abortion Providers
discouraged from seeking abortion servic-
es at these clinics. Studies show that
women who come in contact with anti-
abortion protestors view these encounters
as adverse and tend to feel angry and
intruded upon.61 In places where these
clinics are the sole providers of abortion
services, anti-abortion harassment can, in
effect, prevent women from accessing
abortion services. 
Anti-abortion harassment discourages
some providers from offering abortion
services. Fewer providers means women’s
access to abortion services is further limit-
ed. Harassment aimed at providers
includes violence (e.g., murder and
assault), threats of violence (e.g., attempt-
ed murder, bomb threats, stalking), and
clinic blockades.62 Providers may have dif-
ficulty hiring clinic staff because of the
risk of violence or harassment. Even low
level harassment has a dampening effect
on the hiring of medical and nonmedical
staff.61 Providers may also face other barri-
ers as a result of harassment, such as costs
of increased security, increased insurance
rates, and legal fees to fight harassment.
The Potential Solution:
Medical Abortion Could Improve
Women’s Access to Abortion
• Medical Abortion Could Increase the
Number of Abortion Providers.
Increasing the number of providers has
the potential to increase access to abor-
tion services. Providers who have been
afraid of being targeted by anti-abortion
protesters may feel safer offering medical
abortion because of its greater privacy.
Prior to FDA approval many providers
expressed interest in providing mifepris-
tone-induced abortions should the
approval be granted.63, 64
• Medical Abortion Could Increase the
Types of Providers. Medical abortion is
safely administered by practitioners in
specialities outside of obstetrics/gynecol-
ogy, such as family practice, as well as by
nurse practitioners, nurse midwives, and
physician assistants. Continuing this
expansion to providers of different spe-
cialties and advanced practice clinicians
could make abortion services more wide-
ly available.64-66 There is nothing unique
to medical abortion that is outside the
scope and practice of advanced practice
clinicians (e.g., pregnancy testing, coun-
seling, estimating gestational age by exam
and ultrasound, medical screening,
administering medications, post-abortion
follow-up care, performing uterine re-
aspiration for incomplete abortion).
However, the ability of advanced practice
clinicians to offer medical abortion varies
by state (see Chapter 4).
• Medical Abortion Could Improve the
Geographic Distribution of Abortion
Providers/Services. By providing medical
abortion through advanced practice clini-
cians and those who previously did not
offer surgical abortion, access to abortion
services could expand into geographic
areas where service provision is limited or
entirely lacking. Women in non-metropol-
itan areas, rural areas, and in Midwestern
and Southern states could see an increase
in the number of abortion providers. 
• Medical Abortion Could Expand
Abortion Services Beyond Abortion
Clinics. The majority of abortions are pro-
vided at specialty abortion clinics.2
Medical abortion, however, could be
made available in private medical offices.
Including abortion services with other
gynecological care ensures that women
have access to coordinated and compre-
hensive health care.60
S E C T I O N  I I :  W H Y  M E D I C A L  A B O R T I O N  A N D  W H Y  N O W ? 17
S
ec
tio
n 
2
• Medical Abortion Could Decrease
Violence and Harassment of Patients,
Providers, and Clinic Staff. With medical
abortion, women may no longer be limit-
ed to seeking care from a specialty abor-
tion clinic with the potential for harass-
ment by anti-abortion protesters. If the
number and type of providers expands, it
might be possible for many more women
to go to private practice physicians to
obtain medical abortions. The increase in
privacy and confidentiality could mean
less harassment of women seeking to
have an abortion. If abortion services
move into the practices of those provid-
ing more general reproductive health
care, abortion providers and clinic staff
may be less visible and identifiable. Less
visibility could make it more difficult for
abortion protesters to target those provid-
ing abortion services.
Options in Abortion Methods
The Obstacle: 
Limited Options for Abortion
Clinical abortion services in the U.S. have
remained relatively unchanged for over a
decade.67 For example, women are usually
advised to wait until at least six weeks gesta-
tion to schedule an abortion. Also, the same
surgical techniques used for an abortion at 6-
7 weeks gestation are also generally used at
11-12 weeks gestation. However, women who
have had a choice of methods have reported
higher levels of satisfaction with the abortion
procedure, regardless of the method chosen.68
• Women Need an Option That Can Be
Used Early in Pregnancy. As a general
rule, surgical abortion is not performed
earlier than six weeks since the last men-
strual period (LMP). Medical abortion can
be performed as soon as a woman knows
she is pregnant (as early as one week after
fertilization)69 and up to 63 days since
LMP.30 This is important because abortion
is safest when used early in pregnancy
(<13-14 weeks), with the lowest rates of
complications occurring among women
undergoing abortion at eight weeks LMP
or less.70 In addition, some women like
early methods so they do not need to wait
weeks to terminate a pregnancy.71
• Women Need Abortion Options
Appropriate to Their Life Circumstances.
Women need options that fit their person-
al circumstances.72 Issues such as the
direct and indirect costs involved in hav-
ing an abortion (e.g., cost of the proce-
dure itself, time lost from work), the
availability of social support, the atti-
tudes of intimate partners about abortion,
personal religious and cultural beliefs,
and phase of life (e.g., teenagers, young
adult, and mid-life women) influence a
woman’s choice of abortion method.
What a woman wants at one point in her
life may be different from what she wants
later in life, given the many ways in
which women’s lives change over time.
Women need to be able to choose a
method that is consistent with who they
are and what their circumstances are at
the time they are seeking an abortion.
• Women Differ in Their Preference for
Abortion Methods. Women differ with
respect for their preferences for certain
characteristics of abortion methods.49, 72-77
Some women prefer medical abortion
because they say the experience feels
more natural, is more private, and allows
them more control over the experience.
Other women prefer medical abortion
because they prefer a method that can be
used early in pregnancy or allows them
to avoid surgery. Alternatively, some
women prefer surgical abortion because
they want anesthesia and a clinician in
attendance. Some women also prefer sur-
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gical abortion because it is quick and
completed in one visit.
The Potential Solution: Medical
Abortion Offers Women Options 
in Abortion Methods
• Women Find Medical Abortion
Acceptable. In order for medical abortion
to increase options for women, women
must be willing to use it and find it
acceptable. The majority of women who
have used medical abortion say they were
satisfied with the method. Studies have
shown that more than 85% of women
who had either a mifepristone- or
methotrexate-induced abortion were
moderately or very satisfied with their
medical abortion experience.22, 49, 55, 56, 73, 77, 78
• Medical Abortion Provides Women with
a Choice of Abortion Method. Until
recently, the only option women in the
U.S. had for terminating a pregnancy was
a surgical abortion. Now women can
choose between surgical and non-surgical
methods of pregnancy termination. This
is a major breakthrough in abortion care. 
Offering women options means women
can choose the method that is most suit-
able to their needs and life circum-
stances. Given a choice of abortion
method, women are more satisfied with
their abortion experience.68, 76
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These results were drawn from a nationally representative sample of U.S. health
care providers, including obstetrician/gynecologists, family practice physicians,
nurse practitioners, and physician assistants. The sample includes those who do
and those do not perform surgical abortion. 
Methotrexate
Mifepristone
Somewhat Likely
Very LikelyOBs
FPs
NPs/PAs 23% 54%
32%
28%
13% 45%
26% 54%
31%
Somewhat Likely
Very LikelyOBs
FPs
NPs/PAs
3%
12%
8%
16%
2%
10%
3%
19%
9%
Likelihood of providing mifepristone 
and methotrexate in the next year
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• Medical Abortion Offers Women an
Option That Can Be Used Early in
Pregnancy. Early abortion means safer
abortion. The longer a pregnancy pro-
gresses the greater the medical risks in
terminating the pregnancy.70 Although
surgical abortion can be performed safely
at six weeks or less LMP,79 one source
says many providers wait until a woman
is seven weeks LMP to schedule an abor-
tion.47 Medical abortion is a safe method
that can be used as soon as a pregnancy
is confirmed by clinical exam, a pregnan-
cy test, or ultrasound examination.47, 69
Some providers and clinics require visu-
alization of a gestational sac on ultra-
sound prior to performing an abortion;80
the gestational sac becomes visible at
approximately 35 days LMP.81
• Providers Find Medical Abortion
Acceptable. Because medical abortion is
a relatively new procedure in the U.S.,
there are few surveys of medical abortion
providers. The available evidence gener-
ally indicates that providers have positive
attitudes regarding medical abortion.64, 65,
82-87 Medical abortion providers report that
they like mifepristone and methotrexate
because both are safe and effective in ter-
minating early pregnancy. Many
providers also like being able to offer
women a choice of abortion methods.65, 88,
83 These providers believe that giving
women a choice increases the quality of
care that women receive and gives them
greater satisfaction.
In summary, medical abortion has the poten-
tial to increase access to abortion services in
the U.S. and provide women with an alter-
native to surgical abortion. However, neither
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“You have to process it through your own situa-
tion. Maybe you have economic problems or
strong religious feel-
ings or whatever. I
don’t think the medical
facts are the be all end
all of the situation.” 
“I like the fact that you pass it yourself, which
is good. It is basically a miscarriage. Instead of
having it sucked out
of you, you pass it out
yourself, which is, I’m
sure, a little bit easier
on your uterus . . .” 
“...I feel like it’s easier for a person who is a
mother . . . it’s easier to take say 2 hours in
one day rather than to save 2 days and many
hours in each of those days. Using [mifepris-
tone] takes more
time than is neces-
sary . . . I think [sur-
gical abortion] is
more convenient.” 
What Women Say
Source: Harvey SM, Beckman LJ,
Branch MR. The relationship of con-
textual factors to women’s perceptions
of medical abortion. Health Care
Women Int. 2002;23(6-7):654-665.
Source: Harvey SM, Beckman LJ,
Castle MA, Coeytaux F. Knowledge
and perceptions of medical abortion
among potential users. Fam Plann
Perspect. 1995;27(5): 203-207. 
Source: Harvey SM, Beckman LJ,
Branch MR. The relationship of con-
textual factors to women’s perceptions
of medical abortion. Health Care
Women Int. 2002;23(6-7):654-665.
A Women’s Perspective: “Give women a choice. If they’re
gonna both [RU 486 and vacuum aspiration] be there, I
mean, you can decide what’s right for you at the time.”
Data Source: Harvey SM, Beckman LJ, Branch MR. The relationship of contextual factors to
women’s perceptions of medical abortion. Health Care Women Int. 2002;23(6-7):654-665.
the potential of medical abortion to improve
the lives of women nor its proven safety and
effectiveness have ensured medical abor-
tion’s availability. In the following chapter,
we discuss the role of politics and restrictive
legislation on abortion practice, and what
the impact of these may be on the practice of
medical abortion.
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Mifepristone
Author/s & Year Sample
% that found 
the method 
satisfactory
% that would
choose the 
method again
% that would 
recommend the
method to others
Schaff et al., 1999 933 women 94% 87% 85%
Winikoff et al., 1998 2121 women 88% 92% 96%
Beckman & Harvey, 1997 262 women 89% 87% 94%
Methotrexate 
Author/s & Year Sample
% that found 
the method 
satisfactory
% that would
choose the 
method again
% that would 
recommend the
method to others
Harvey, Beckman, 
& Satre, 1999
186 women 82% 93% 78%
Wiebe, 1997 116 women Not reported Not reported 84%
Crenin & Park, 1995 86 women 79% 89% Not reported
A Provider’s Perspective: “I am really pleased with [methotrexate] . . . I like
that the woman is a participant in the procedure and she has control over
it. Not like surgery where the woman is just a passive observer having
something done to her body. I think it results in women who are ultimately
more satisfied with their decision since they were part of the process.”
Data source: Harvey SM, Beckman LJ, Satre SJ. Experiences and satisfaction with providing methotrexate-
induced abortions among US providers. JAMWA. 2000;55(3 Supp):S161-163.
Acceptability of Mifepristone and Methotrexate to U.S. Women
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Authors Date Sample Relevant Findings
Ellertson, C., et al.,
1999
1995-96
Interviews: n=78, focus
groups: n=18 providers
(physicians, midlevel providers,
counselors) from 17 sites
Providers reported being generally satisfied with mifepristone. Most
thought midlevel providers could perform mifepristone abortions
with physician backup. Staff at all but one site want to offer mifepri-
stone if approved by the FDA.
Harvey, Beckman,
& Satre, 2000
1997
N=76 providers from 17 sites
offering methotrexate abor-
tions (physicians, midlevel
providers, administrators,
counselors)
80% were satisfied or extremely satisfied with methotrexate. The
mean satisfaction rating was 3.9 on a scale from 1 to 5. No physi-
cian or midlevel provider rated satisfaction as less than a 3. Five of
the 12 respondents who voluntarily mentioned mifepristone had a
clear preference for mifepristone over methotrexate.
Heilig, 1992 1991
N=466 random sample of
OBs in California
48% had followed the RU-486 story "closely" and 45% followed it
"somewhat closely." 14% were opposed to abortion and wouldn't
use RU-486 if available. 69% thought RU-486 should be made
available now to patients for abortion. 91% of those who currently
provide abortions (n=255) would use RU-486. 32% of those who
currently do not provide abortions (n=209) would use RU-486.
Joffe, 1999 1996
N=25 National Abortion
Federation members (physi-
cians, midlevel providers,
counselors)
Providers who performed mifepristone and/or methotrexate abor-
tions were generally satisfied with the process. All thought midlevel
providers could perform medical abortions. Providers' worst fears at
the outset were not realized (patient going to emergency room with
hemorrhaging or patient not returning for required additional visits).
Some providers saw the need for dating pregnancies (using ultra-
sound machines) as an obstacle for providers who are not surgical
abortion providers. 
McKee & Adams,
1994
1991 N=1208 nurse-midwives
57% would want authority to prescribe RU-486 if approved by the
FDA. 25% would incorporate abortion procedures into their own
practices, if allowed. 19% would perform abortions in the an abor-
tion clinic, if allowed. 52% would vote anonymously in favor of
allowing nurse-midwives to perform abortions.
Miller, Miller, &
Pinkston Koenigs,
1998
1996
N=668 physician members of
the Society for Adolescent
Medicine
96% agreed that abortion should be available to pregnant adoles-
cents under some or all circumstances. 42% would prescribe
methotrexate or RU-486 for abortion if FDA-approved and physi-
cian training was available; 34% were unsure. 54% believed that if
medical abortion becomes routinely available in the United States,
primary care physicians should be allowed to perform them.
Rosenblatt, Mattis,
& Hart, 1995
1994
N=138 providers in rural Idaho
(FPs, OBs, general surgeons)
26% said they would definitely prescribe RU-486 if it became avail-
able; 35% were unsure. About half of those morally opposed to
abortion said they would not refer their patients to another provider
for RU-486.
Rosenblatt,
Robinson, Larson,
& Dobie, 1999
1996-97
N=286 first- and second-year
medical students at University
of Washington
41% believed that RU-486 should be available under "most cir-
cumstances," and 44% believed that it should be available "with
limitations." 62% expected that they would provide RU-486 in
future practice. Female students (69%) were more likely to expect
to provide RU-486.
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Past Research on Health Care Providers' Knowledge, Attitudes,
and Practices Regarding Mifepristone and Methotrexate. 
Why is it that mifepristone, which has
been used safely and effectively by mil-
lions of women worldwide, is so hotly
debated in the U.S.? Why has this drug had
such difficulty coming to market in the
U.S. despite the consistent findings from
research on its safety, effectiveness, and
acceptability? It’s simple: the underlying
objections to mifepristone are not about the
safety and effectiveness of this drug,
although it has often been described incor-
rectly as dangerous by anti-abortion advo-
cates.89 At their core, objections to mifepri-
stone are objections to abortion itself.
Because the right to abortion continues to
be debated so intensely in the U.S.,
mifepristone – a safe and effective abortifa-
cient – has taken two decades to reach U.S.
women. Abortion politics have turned the
rather straightforward study and approval
of this regimen into a prolonged process,
vulnerable to shifts in the political climate.
Below we examine the role of politics in
abortion policy and legislation and how
specific laws and policies may restrict
access to medical abortion.
What Is the Role of Politics 
in Medical Abortion
Legislation and Policy?
It is not yet clear whether the practice of
medical abortion will be subject to the same
policies as surgical abortion, however some
policy makers have targeted medical abor-
tion specifically. An example of the role pol-
itics plays in medical abortion policy is the
proposal of the “RU-486 Patient Health and
Safety Protection Act” (Legislative bills
S251/HR482). First introduced in the U.S.
House and Senate in October 2000, this bill
would have limited access to mifepristone
by imposing restrictions that, according to
the FDA and numerous medical groups, are
unnecessary and do not add to the safety of
mifepristone. These proposed restrictions
include requiring providers of mifepris-
tone/misoprostol-induced abortion to be
trained in surgical abortion, to be certified in
ultrasound dating of pregnancy, to complete
a training program regarding the prescription
of mifepristone, and to have admitting privi-
leges within a one-hour distance from their
principal medical office.90 It is important to
note that the current law and standard of
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care in the U.S. does not mandate that a
health care practitioner who provides prena-
tal care be capable of handling complica-
tions from an incomplete abortion or ectopic
pregnancy. As such, the requirement that
providers of mifepristone be able to handle
these complications singles out these
providers for more stringent regulations than
is standard for medical practice in the U.S.
What Are the Political
Strategies Used to Limit
Medical Abortion? 
Political attacks upon the safety of mifepris-
tone/misoprostol have been the primary
mechanism to limit access to medical abor-
tion. Methotrexate has received less atten-
tion, perhaps due in part to its off-label sta-
tus. The arguments against mifepristone/
misoprostol have focused on essentially
three basic myths: 1) mifepristone is a risky
medication which poses serious health risks
to women; 2) mifepristone was rushed
through the FDA approval process and did
not receive a thorough review of its safety
and effectiveness; and 3) misoprostol is dan-
gerous and poses health risks to pregnant
women. These myths are refuted below.
Myth #1: Mifepristone is a risky drug 
Anti-choice advocates have repeatedly sug-
gested that mifepristone poses serious health
risks to women and that its use should be
limited. They have asserted that mifepris-
tone is a “dangerous drug” which creates
serious and potentially fatal side effects.89, 91
However, a multitude of studies conducted
in the U.S. and abroad which have rigorous-
ly studied the safety and effectiveness of
mifepristone have demonstrated otherwise
(see Chapter 2). The effectiveness of this
drug is precisely what abortion opponents
find objectionable.90
Myth #2: Mifepristone was rushed
through the FDA approval process
Anti-choice advocates claim that mifepris-
tone was hurriedly approved without ensur-
ing health protections for women who
would use it.92 Mifepristone was, in fact,
approved under a special provision of the
FDA review process known as “Subpart
H”.93 Although Subpart H does have a provi-
sion for accelerated review, it can also be
used for the sole purpose of putting restric-
tions on drug distribution. In the case of
mifepristone, Subpart H was not used to
expedite the review process but only to
place restrictions on mifepristone’s distribu-
tion (for the details of these restrictions see
Chapter 2). As a part of the approval
process, the FDA reviewed data from U. S.
clinical trials of mifepristone involving over
2,000 women, as well as numerous
European studies involving tens of thou-
sands of women, which demonstrated both
the safety and effectiveness of this medica-
tion for early pregnancy termination. 
Myth #3: Misoprostol is dangerous
to pregnant women 
Myths about misoprostol, the drug used in
conjunction with both mifepristone and
methotrexate, have also circulated. Without
misoprostol as a part of the regimen, the
effectiveness of both mifepristone and
methotrexate is significantly decreased.
Therefore, the availability of misoprostol is
crucial for the practice of medical abortion.
One myth about misoprostol is that it is dan-
gerous to women. The story behind this par-
ticular myth is told below. 
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• The Searle Letter. In August 2000, G. D.
Searle & Co., the pharmaceutical manu-
facturer of the drug misoprostol (market-
ed as Cytotec®), issued a letter in which
it warned physicians that misoprostol
should not be used with pregnant
women because it can cause abortion.94
In addition, Searle argued that the risks
to a developing fetus exposed to miso-
prostol when used for labor induction or
cervical ripening (the thinning, soften-
ing, and opening of the cervix) had not
been determined. The letter was imme-
diately picked up by anti-choice advo-
cates, including members of Congress,
who reported that misoprostol was dan-
gerous and could cause a woman’s
uterus to “explode”.95 Thus, the Searle
letter was used to argue against medical
abortion, suggesting that it is dangerous
and threatens the health of women in
the U.S.
• The Medical Community Responds. The
American College of Obstetrics and
Gynecology (ACOG), the primary profes-
sional organization of physicians engaged
in the science and practice of women’s
reproductive health care in the U.S.,
responded to the Searle letter. In 1999
ACOG had carried out its own review of
the many published studies on the use of
misoprostol for labor induction and con-
cluded that misoprostol was safe and
effective for inducing labor.96 In October
2000 ACOG sent the FDA an updated
report of the research data on misopros-
tol, including studies on its use for med-
ical abortion. In a statement which
accompanied the report,97, 98 ACOG noted
that the serious side effects cited in the
Searle letter involved higher doses of
misoprostol and were relatively rare.
ACOG also highlighted the strong safety
record of misoprostol when used appro-
priately and presented guidelines to min-
imize the potential for adverse events,
although adverse events were already
rare. ACOG also questioned the timing of
the Searle letter which had been issued
just a few weeks prior to the FDA
approval of mifepristone. ACOG clarified
the important role of misoprostol as a
reproductive health drug beyond its role
as an abortifacient and included a point-
by-point refutation of proposed FDA
restrictions for the mifepristone/miso-
prostol regimen put forth by anti-abortion
Congressional representatives. The FDA
ultimately rejected these restrictions.
• FDA Gives Misoprostol A New Label. In
April 2002, the FDA announced that it
changed the label for misoprostol (known
by the brand name Cytotec®).99
Misoprostol is sometimes used to reduce
the risk of stomach ulcers. In recognition
of this, the new label says pregnant
S E C T I O N  I I I  —  W H A T  A R E  T H E  P O L I T I C A L  A N D  L E G A L  B A R R I E R S ?  25
“...The American College of Obstretricians and
Gynecologists (ACOG) is concerned by the
content, timing, and tone of [the Searle] letter.
Given that misoprostol is commonly employed
in conjunction with mifepristone (RU 486) to
achieve nonsurgical early pregnancy termina-
tions, the arrival of the Searle letter within
weeks of the U.S. Food and
Drug Administration’s (FDA’s)
approval of mifepristone could
limit the use of the new option
for reproductive choice. Also,
although the letter correctly points out the
potentially serious, but relatively rare, risks of
misoprostol when employed for cervical ripen-
ing and labor induction, it fails to comment on
the extensive clinical experience with this
agent and the large body of published reports
supporting its safety and efficacy when used
appropriately.”
Excerpt from ACOG letter
from a the ACOG letter by
Stanley Zinberg, MD,
to Janet Woodcock, MD,
Director of the FDA,
October 26, 2000.
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women should not use the drug for this
purpose. The Searle label had stated that
pregnant women should not take the drug
under any circumstances. The FDA said
that it clarified the warning to reflect that
“the drug has a recognized use by obste-
tricians and gynecologists to induce
labor, delivery and is part of the FDA-
approved regimen for use with mifepris-
tone to induce abortion.”99
What Are the Laws and
Policies That May Restrict
Access to Medical Abortion?
Laws governing abortion, which may also
apply to medical abortion, vary widely from
state to state. However, several state laws
deserve particular attention because they are
likely to be applied to medical abortion prac-
tice. Although not a comprehensive review
of state laws, the paragraphs below describe
several types of legal statutes which have
become common across the U.S. and that
may impact the availability of medical abor-
tion services. Anyone wishing to determine
legal issues pertaining to a particular state
should check the laws governing that state. 
Laws That Restrict the Provision 
of Medical Abortion 
Physician-Only Laws
Most states have laws which restrict the pro-
vision of abortion to licensed physicians.
One survey found that only six states
(Arizona, Kansas, New Hampshire, Oregon,
Vermont, and West Virginia) did not have
such laws.100 In some states, however, these
laws may not preclude non-physicians from
performing medical abortion because their
statutes have defined abortion very narrowly
(e.g., as a surgical procedure). In other
states, such as New York, Montana, and
Rhode Island, rulings by administrative
agencies or state courts supercede physi-
cian-only laws and permit certain non-
physician practitioners to provide medical
and/or surgical abortions.101-104 In addition, if
laws are interpreted consistent with the
standard of care (i.e., standard medical prac-
tice), physicians may delegate tasks to
“qualified agents” such as physician assis-
tants. Such a legal interpretation may allow
for the provision of medical abortion by
advanced practice clinicians working under
the supervision of a physician.105, 106
Dispensing Authority Laws
Physicians generally have authority to pre-
scribe any FDA-approved drug, although
some states have enacted restrictions. In
states with restrictive dispensing authority
laws, dispensing drugs for medical abortion
may be limited to licensed physicians.100, 106,
107 Several states have laws granting dispens-
ing authority to advanced practice clini-
cians (i.e., nurse practitioners, physician
assistants), either as independent practition-
ers, under the supervision of a licensed
physician, or under collaborative prescrib-
ing agreements with physicians. By restrict-
ing dispensing authority, these laws directly
impact the ability of advanced practice cli-
nicians to engage in the provision of med-
ical abortion.
TRAP Laws
Targeted Regulation of Abortion Providers
(TRAP) laws consist of laws that single out
abortion providers and facilities where abor-
tions are performed and impose on them reg-
ulations not applied to other physicians or
outpatient clinics. For example, TRAP laws
can restrict abortion practice when they
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require special licensing and/or physical
plant specifications that are burdensome to
meet. Requirements vary widely by state and
can include licensing of the abortion
provider, state inspections of the medical
facility, room air exchange rates, and mini-
mum space requirements surrounding beds
in recovery areas.100, 106, 108
Requirements sometimes are applied only to
those facilities that provide a certain volume
of abortion services.106 For new providers of
abortion in states with requirements target-
ing only high volume abortion facilities, the
existing TRAP laws may not apply if the
facility only performs medical abortion on
an occasional basis as a part of a general
health care practice. However, for providers
who perform higher numbers of medical
abortions, attempts may be made to apply
these statutes to medical abortion as well.105
Laws Regarding Examination 
and Disposal of Fetal Tissue 
Several states have laws that require the
examination of the aborted tissue by the
physician performing the abortion and/or a
pathologist. In a review of related laws,106 13
states had fetal tissue examination laws
which on their face may be applicable to
medical abortion. The person designated to
examine the tissue varies from state to state,
with some laws specifying their applicabili-
ty only to abortions performed in certain
types of facilities. Many states also have
laws about the disposal of fetal tissue. These
laws vary widely by state and may require
burial, cremation, or incineration. The
applicability of these laws to medical abor-
tion is unclear and to date they have not
posed a barrier to medical abortion practice.
Compliance with a fetal tissue examination
or disposal law would obviously be difficult
for a medical abortion provider if the
woman expels the tissue some place other
than the provider’s office.100, 106
Laws That Restrict 
Women From Obtaining 
Medical Abortion 
Abortion-related laws that on their face
appear to protect women’s health and safety
may, in practice, result in delaying women
from obtaining abortion. By delaying abor-
tion, these laws may actually increase health
risks to women. 
Informed Consent Laws 
The term informed consent refers to ensur-
ing that a patient understands what is
involved in a treatment or procedure, the
potential risks and benefits, and any avail-
able alternatives. This process ensures that
the patient has the information necessary to
make an informed choice about undergoing
the treatment or procedure. Informed con-
sent is important to the health and safety of
women obtaining an abortion. Informed con-
sent consists of a full description of the pro-
cedure involved, the potential risks, and the
treatment alternatives. However, informed
consent laws written specifically for abortion
require adding biased language and/or pro-
cedures to the informed consent process.
Many states have laws which specify in the
consent form scripted language unrelated to
the risks, benefits, or alternative treatments
for pregnancy termination, and in essence
act to discourage women from having an
abortion.100 Discouraging a woman from hav-
ing an abortion is outside the scope of
informed consent and does nothing to
improve a woman’s understanding of the
risks of a given abortion procedure and the
alternative procedures that might be used.
Furthermore, state-mandated informed con-
sent procedures can also act as barriers to
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abortion. In some states this state-mandated
information must be provided by the physi-
cian in person; in others it can be delegated
by the physician to other staff or provided
via written materials which can be mailed.107,
109 The practical results of this type of legis-
lation are twofold: 1) the language in state-
scripted informed consent compels
providers to discourage women from choos-
ing abortion, and 2) the added consent pro-
cedures cause delays in access to abortion.
Thus, informed consent legislation written
specifically for abortion makes the consent
process biased and extremely cumbersome. 
Waiting Period Laws
Waiting period laws require a delay of a
specified length between the request for an
abortion and the provision of an abortion.
The length varies from state to state (e.g.,
Indiana, 18 hours; Tennessee, 48-72 hours)
with the most common waiting period being
24 hours.109 In some states, the waiting peri-
od begins after state-mandated in-person
abortion counseling has been performed.107, 109
Waiting period laws pose a significant barri-
er to women seeking medical abortion
because they delay the initiation of abortion.
Medical abortion is a regimen that is most
effective early in pregnancy and therefore
needs to be done in a timely manner. The
delays introduced by waiting periods may
make medical abortion impossible.
Parental Involvement Laws 
Many states require some sort of parental
involvement when a minor seeks an abor-
tion.106 At least one state (Tennessee) has
specifically indicated the applicability of
parental notification to medical abortion.110
Parental involvement laws can delay access
to abortion. A young woman, for example,
may put off her decision while struggling
with how to tell her parents. In addition,
judicial bypass – whereby a young woman
may seek permission for abortion from a
judge rather than from one or both parents –
also takes time. The delay introduced by
these parental notification laws is significant
given that medical abortion can only be per-
formed early in pregnancy. 
Public Funding Issues 
All states are prevented from providing fed-
eral Medicaid funding for abortion for low-
income women except in cases of rape,
incest, or when the pregnant woman’s life is
endangered (a provision known as “the
Hyde Amendment”).100, 107 Some states use
state money to provide funding for abortions
for low-income women, either voluntarily or
when state courts have interpreted their
respective constitutions broadly on the issue
of reproductive health rights. On March 30,
2001 the U.S. Department of Health and
Human Services notified state Medicaid
directors that the federal Medicaid funding
restrictions for surgical abortion also apply
to medical abortion.111 In addition to funding
the procedure, use of public facilities has
also been banned in state laws. In 1989 the
U. S. Supreme Court upheld a Missouri state
law which banned the use of public facilities
for the provision of abortion except to save
the life of the woman. In some states, courts
have struck down efforts to prevent the use
of public or quasi-public facilities for the
provision of abortion services.107
What Are the Challenges
Ahead?
In the coming months and years, several
legal and political issues that may have an
impact on access to and provision of med-
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ical abortion services will be debated. Some
of these issues are described below.
FDA Approval of Mifepristone 
The FDA may be pressured by anti-choice
advocates to re-examine and possibly over-
turn its approval of mifepristone, or at a
minimum to increase the restrictions placed
on its provision. A new commissioner of the
FDA is appointed by each new administra-
tion. Future commissioners may consider
revisiting the approval of mifepristone.
Whether or not the FDA will yield to politi-
cal pressures to undo its prior approval of
mifepristone is unclear.
Proposed Legislation to Limit 
the Use of Medical Abortion 
Several types of legislative bills and other
policy changes have been proposed in both
federal and state legislative bodies that
would affect the availability of medical abor-
tion. These include banning drugs used in
medical abortion regimens and refusal (“con-
science”) clauses. These types of policies
and their relevance to medical abortion
access are described below.
• Banning Drugs Used in Medical
Abortion Regimens. In some states there
have been attempts to ban drugs used in
medical abortion regimens. In Michigan
such an attempt was successfully chal-
lenged. The Michigan bill would have
banned any drug for abortion that was
not FDA-approved for a medically-
induced abortion by banning such drugs
from state-mandated abortion
counseling.107, 112 Although mifepristone
and misoprostol have since been
approved by the FDA for use in medical
abortion, methotrexate is still used off-
label for medical abortion and would
have been banned by this statute. 
• Refusal Clauses. Refusal clauses allow
individual health care professionals to
refuse to provide services to which they
say they have moral objections, such as
emergency contraception or abortion. For
example, this type of legislation has been
introduced in Kentucky113 to allow phar-
macists to refuse to fill prescriptions for
medications “whose primary purpose is
to terminate a pregnancy.” Currently,
mifepristone is distributed only to physi-
cians who, in turn, dispense the drug to
patients (see Chapter 2), therefore this
type of legislation is unlikely to impact
access to mifepristone. However, should
misoprostol be prescribed for women to
take at home, or if the FDA regimen were
changed to allow for provision of mifepri-
stone through pharmacies, this type of
legislation could restrict women’s access
to medical abortion. 
In summary, political and legal barriers con-
tinue to threaten women’s access to medical
abortion services in the U.S. The main anti-
choice argument against medical abortion is
that mifepristone is unsafe. However, this
accusation is clearly refuted by the wealth of
available scientific studies that document its
safety and effectiveness. A common mecha-
nism for limiting access to medical abortion
is legislation introduced at both the federal
and state levels. One of the primary ways in
which laws impact medical abortion is by
creating delays in initiating an abortion (e.g.,
waiting laws, informed consent laws,
parental notification laws). Clear, under-
standable information about the safety and
effectiveness of the two main medical abor-
tion regimens (mifepristone/misoprostol,
methotrexate/misoprostol) is crucial in this
ongoing public debate. Next, we turn our
attention to barriers faced by health care
providers in the provision of medical abor-
tion services.
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The practical realities of providing a new
medical technology to patients can be barri-
ers to service provision. With medical abor-
tion services, even surgical abortion
providers must learn new protocols, train
staff, and adjust their practices to the new
service they are providing. More information
is needed regarding obstacles to initiating
medical abortion services as well as reasons
why some providers decide not to offer med-
ical abortion. A study of abortion providers
conducted in 2000 (prior to the FDA
approval of mifepristone) reveals that,
although there were many who experienced
more than one major obstacle to establishing
medical abortion services, most of those
obstacles diminished or disappeared once
services were in place.114 However, some
obstacles to the provision of medical abor-
tion remained. Barriers encountered by
providers initiating medical abortion servic-
es are described below.
Additional Staff Training 
and Time Needed to Counsel
Women Regarding the
Medical Abortion Regimen 
Increased time for counseling patients and
the need for training in medical abortion
counseling are commonly reported obsta-
cles in establishing medical abortion servic-
es.83, 88, 114 However, once begun, some abor-
tion providers also reported that service
provision became routine after relatively
few procedures.114 This finding suggests that
although training staff in medical abortion
counseling and the increased time needed
to perform medical abortion counseling
were obstacles, these aspects of service pro-
vision were less problematic once clini-
cians and staff became accustomed to the
new procedures.
Multiple Office Visits 
for Administration 
of Medical Abortion
Because the FDA-approved regimen requires
in-office administration of both mifepristone
and misoprostol, a mifepristone-induced
abortion done according to this regimen
takes a minimum of three office visits as
compared to the two recommended for sur-
gical abortion. While the FDA regimen
requires in-office administration of miso-
prostol, there are many studies which have
demonstrated the safety of home administra-
tion.75, 115, 116 Abortion providers cited the
logistics of multiple office visits as one of
the main obstacles to initiating abortion
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services.88, 114 Simplifying the medical abor-
tion regimen by reducing the number of vis-
its (for example by allowing patients to
administer the misoprostol at home) could
eliminate this obstacle. There is anecdotal
evidence that many providers are utilizing
evidence-based regimens which eliminate
the second clinic visit.117 Eliminating the sec-
ond visit can be done without compromising
safety or effectiveness.36, 118 However, the
post-treatment examination is necessary to
confirm completion of a medical abortion. If
a pregnancy continues after either a mifepri-
stone/misoprostol or a methotrexate/miso-
prostol abortion, birth defects are possible.
Ultrasound Examination
Neither the FDA requirements nor the
Prescriber’s Agreement stipulates ultra-
sound use or training as a requirement for
prescribing mifepristone. However, some
providers confirm an intrauterine pregnancy
by ultrasound to avoid missing an ectopic
pregnancy.119 Providers have cited additional
staff training in vaginal ultrasound as an
obstacle to providing medical abortion serv-
ices.83, 114 Anti-choice legislators have pro-
posed requiring abortion providers to be
certified in ultrasound evaluation as a con-
dition for prescribing mifepristone,90 and
similar proposals aim to restrict who may
perform the ultrasound examinations.
Training needs and restrictions on the per-
formance of ultrasonic examinations could
be significant obstacles to the provision of
medical abortion.
Access to Surgical Back-up
for Incomplete Medical
Abortion
Providers of medical abortion need to be
able to provide surgical abortion or have a
referral plan for that service if a medical
abortion is incomplete. The availability of
back-up for those rare cases of complica-
tions following medical abortion is impor-
tant for protecting women’s health and safe-
ty. Back-up arrangements are consistent
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Obstacle N* %**
Time for counseling 18 72
Training in counseling 16 64
Logistics of multiple visits 13 52
Training in vaginal ultrasound 10 40
Training in medical abortion procedure 9 36
* Total N=41
** Total does not equal 100% because subjects were permitted to name multiple obstacles.
Top 5 Major Obstacles to Initiating 
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with the American College of Obstetrics and
Gynecology’s guidelines for provision of
medical abortion9 and is an FDA require-
ment for providing mifepristone.17 Most
providers of women’s health care already
have referral plans for their patients who
experience a spontaneous abortion (i.e.,
miscarriage) and need surgical completion.
Nonetheless, securing back-up for medical
abortion may present difficulties for some
providers. Providers in rural areas, in par-
ticular, may have difficulty finding access to
surgical back-up. Although surgical back-up
usually refers to electric vacuum aspiration,
manual vacuum aspiration (MVA) is another
surgical abortion method which may be a
better option for some providers because it
is an easy-to-learn method and the instru-
ments are inexpensive and portable. MVA
has been used for many years throughout
the world for spontaneous and incomplete
first trimester abortion and is as safe and
effective as electric vacuum aspiration.120
Because the provider uses a handheld
syringe as a source of suction, MVA can be
used in many different settings, including
those without the equipment necessary for
electric vacuum aspiration.121
Malpractice Insurance Issues 
Clinicians are required to notify their mal-
practice insurance carriers of any significant
additions or changes to their medical prac-
tice. New providers of medical abortion who
have not already been providing surgical
abortion will most likely have to report the
addition of medical abortion. Not all mal-
practice insurance companies cover abortion
services, thus, some providers may need to
change carriers.100 In some cases, adding
medical abortion services may result in
increased malpractice insurance premiums,
potentially discouraging providers from
adding this service to their practice.
Third Party Reimbursement
Reimbursement from third party payers (i.e.,
Medicaid and commercial health plans) is a
potential barrier particularly for primary
care providers because their reimbursement
rates for office visits tend to be lower than
those of specialists (such as obstetrician/
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Advantage N* %**
Clients want services 26 100
Staff likes new skills 24 92
Cutting edge of technology 23 88
Less stress for clients 21 84
Staff prefers earlier services 14 54
* Total N=41
** Total does not equal 100% because subjects were permitted to name multiple obstacles.
Top 5 Advantages to Offering 
Medical Abortion Services
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gynecologists) and may be insufficient to
recover costs. Inadequate reimbursement
may discourage primary care practitioners
from adding medical abortion services to
their medical practice.122, 123
Additional Obstacles 
for New Abortion Providers
Compared to those who are already provid-
ing surgical abortion, practitioners who have
never before offered abortion services may
have additional obstacles because they may
need to address general issues related to the
provision of abortion services for the first
time. These providers will need to train staff
in abortion counseling, establish informed
consent procedures and forms, learn about
and establish procedures to comply with
state laws regarding abortion practice, buy
ultrasound equipment and obtain training in
its use, establish fees for medical abortion
services, and arrange for surgical back-up. In
addition, the potential barriers of increased
malpractice insurance premiums and third
party reimbursement are relevant to new
abortion providers as well. 
New practitioners may also have a variety of
concerns about adding medical abortion
services, including reactions from their col-
leagues, staff, family members, and commu-
nity, as well as reactions of board members
at hospitals where they have admitting privi-
leges.124 Taken together, the practical realities
of setting up a new service and the political
and personal costs of becoming an abortion
provider may discourage some providers
from initiating medical abortion services. 
In summary, health care providers who
choose to offer medical abortion services as
part of their practice may encounter the
same obstacles as they do when offering any
new medical technology, such as additional
training for themselves and their staff.
However, other obstacles are unique to med-
ical abortion, including the time associated
with multiple office visits and financial con-
siderations associated with malpractice
insurance and third party reimbursement. In
the following chapter, we outline recommen-
dations for making medical abortion easier
to provide and more accessible to women.
34
Medical abortion represents a significant
advance in abortion practice. Until recently,
surgical abortion was the only type of abor-
tion available to women seeking early preg-
nancy termination. Now women can choose
between surgical and medical abortion
methods. Whereas access to surgical abor-
tion has become increasingly restricted,
especially for women living in rural areas,
medical abortion has the potential to
increase the number, types, and geographic
distribution of abortion providers and
reduce other barriers to access. 
Medical abortion could change the land-
scape of abortion practice in the United
States. If institutional and governmental
decisions were based solely on scientific
knowledge and consideration of women’s
health, medical abortion already would be
widely available and more commonly used.
However, other factors influence, and at
times overwhelm, legislative and policy-
making processes in the U.S. As a conse-
quence, the laws, rules, and operational and
judicial decisions that constitute abortion
policy (as well as the private policies of
hospitals and other health care organiza-
tions) are subject to political bargaining,
ideological biases, and the preferences of
powerful interest groups. 
In the previous chapters, we have exam-
ined some of the barriers to the provision
of and access to medical abortion in the
U.S. In this chapter, we present recommen-
dations for policymakers and legislators
aimed at increasing the availability of med-
ical abortion. 
Recommendations
Increase public awareness 
of the science and policies
regarding medical abortion
The following recommendations are intend-
ed to correct misinformation about medical
abortion, and to increase public awareness
and understanding of the safety and effec-
tiveness of medical abortion as demonstrated
by medical and pubic health research.
• Support the development of national
media campaigns to inform women about
the availability, safety, and effectiveness
of medical abortion. 
• Support the availability of information
regarding medical abortion in public clin-
ics and health facilities, and publicly
funded outreach programs.
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• Provide the public with critical analysis of
the impact of changes in laws and policy
upon the availability of medical abortion.
Base policy decisions on the
public health science of medical
abortion
The following recommendations are intend-
ed to ensure that policy decisions at all lev-
els of government are made in the interest of
women’s health.
• Develop policy statements based on sci-
entific research that include the positions
of leading professional organizations
(e.g., American College of Obstetrics and
Gynecology, American Medical Women’s
Association, and the American Public
Health Association).
• Rely on public health and medical
research findings when developing and
evaluating laws that could affect the
availability of medical abortion.
Increase types of providers 
who perform medical abortion
The following recommendations are intend-
ed to increase the types of providers who
perform medical abortion by expanding the
practice to advanced practice clinicians (i.e.,
certified nurse-midwives, nurse practition-
ers, and physician assistants).
• Oppose laws that bar advanced practice
clinicians from practicing medical abor-
tion, such as physician-only laws and
laws that restrict prescriptive authority.
• Develop and support programs that pro-
vide education and training for advanced
practice clinicians in medical abortion
regimens.
• Urge professional organizations to devel-
op and offer training, workshops, and
other necessary support to advanced
practice clinicians who want to provide
medical abortion services. 
• Support policies that require training in
medical abortion in schools of nursing.
Increase the number of
physicians who perform 
medical abortion
The following recommendations are intend-
ed to increase the number of physicians who
provide medical abortion services and
enhance providers’ ability to provide med-
ical abortion services.
• Develop and support policies that require
training in medical abortion in medical
schools.
• Support laws and policies that assist
physicians who do not provide abortion,
especially gynecologists and family prac-
titioners, in adding medical abortion to
their practices.
• Connect physicians with existing
resources for the purposes of medical
abortion training and support (e.g.,
National Abortion Federation and The
Abortion Access Project).
• Promote and support expansion of FDA-
approved medical abortion regimens to
include other evidence-based regimens
that have comparable or superior effec-
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tiveness and side effects profiles (e.g.,
methotrexate regimens, home administra-
tion of misoprostol, vaginal administra-
tion of misoprostol, changes in dosage,
and timing of administration of medical
abortifacients). 
• Oppose laws and policies that add legal
barriers to medical abortion practice, such
as TRAP laws, public funding restric-
tions, and laws which attempt to effec-
tively limit providers to use of the FDA
approved regimen (see Chapter 3
“Banning Drugs Used in Medical
Abortion Regimens”).
Increase the number and types 
of health care settings in which
medical abortion is provided
The following recommendations are intend-
ed to increase the number and types of
health care settings in which medical abor-
tion is provided, thereby increasing access
for many women and their choice of abortion
method.
• Overturn and oppose laws that place
unnecessary restrictions on facilities in
which abortions are performed (i.e.,
TRAP laws). 
• Support laws and policies that encourage
providers to offer medical abortion servic-
es in the same facilities as other repro-
ductive health care. 
• Develop and promote incentive programs
to encourage and enable providers to
practice medical abortion in rural areas.
Increase access by making 
it easier for women to obtain
medical abortion
The following recommendations are intend-
ed to increase women’s access to medical
abortion.
• Overturn and oppose laws and other poli-
cies that unnecessarily complicate and
delay the process of obtaining an abor-
tion, such as informed consent laws that
introduce delays in abortion care, manda-
tory waiting period laws, and parental
involvement laws.
• Reform the federal law that prohibits
states from using federal Medicaid money
to fund abortions for low-income women.
Oppose state and federal laws that place
restrictions on public funding and the use
of public facilities in the provision of
abortion services.
Improve women’s knowledge 
of medical abortion
The following recommendations are intend-
ed to increase the understanding of medical
abortion among women seeking early preg-
nancy termination. The acceptability of a
method depends, in part, upon women hav-
ing complete and accurate information.
• Promote laws and policies that provide
for education and counseling of women
seeking abortion services; such education
and counseling must include information
about all abortion methods. 
• Develop and support laws and policies
that provide public funding to make
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available in public clinics medical abor-
tion-related educational materials.
• Support and promote policies that ensure
that education and counseling are cultur-
ally appropriate and specific to various
age, cultural, and social groups. 
Ensuring Access 
to Medical Abortion
The above recommendations are aimed at
making medical abortion easier to provide
and more accessible to women.
Implementing these recommendations will
help create the conditions necessary for
health care providers in the U.S. to offer
medical abortion. Although women’s knowl-
edge about medical abortion is important,
knowledge itself will not improve access to
medical abortion. Access will be guaranteed
by public policies that support women’s
health and the right of each woman to
decide for herself if and when to have chil-
dren. The goal of ensuring access to medical
abortion will be realized with the coopera-
tion of public health professionals, women’s
health advocates, health care providers, poli-
cy makers, journalists, media professionals,
and others who recognize the importance of
abortion access to the health of women,
men, and their families.
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Abortion provider– An individual physician
or advanced practice clinician who offers
abortion services.
Advanced practice clinicians– Health care
professionals, including nurse practitioners,
certified nurse-midwives, and physician
assistants, who are licensed to practice med-
icine with physician supervision.
Anti-metabolite– A drug which interferes
with cell growth by blocking the chemical
reactions necessary for DNA production and
normal cell division. 
Anti-progesterone– A drug which interferes
with the action of progesterone, the hormone
necessary to cease menstruation and main-
tain pregnancy. 
Cytotec®– The brand name for misoprostol
(see Misoprostol).
Ectopic pregnancy– A pregnancy which
occurs outside the uterus, also called an
extrauterine pregnancy. An ectopic pregnan-
cy occurs in about 1 in 60 pregnancies.
Often called a “tubal pregnancy,” most
ectopic pregnancies occur in the fallopian
tubes. However, on rare occasions, the fertil-
ized egg may implant in the ovaries, cervix,
or abdomen. Since the fallopian tubes are
not large enough to accommodate a growing
embryo, the pregnancy cannot continue nor-
mally. If the problem is identified early, the
embryo is removed. In some cases, the
embryo grows until the fallopian tube is
stretched so much that the tube ruptures.
Rupture of the tube is a true medical emer-
gency because of maternal hemorrhage
(severe blood loss). 
Effectiveness– In research studies, effective-
ness usually refers to a drug’s ability to pro-
duce the intended result in a real world set-
ting.
Efficacy– In research studies, efficacy usual-
ly refers to a drug’s ability to produce the
intended result in a clinical trial.
Electric vacuum aspiration– The most com-
mon method of surgical abortion in which a
small tube, or cannula, is attached to an
aspirator machine which is inserted into the
uterus; the contents of the uterus are then
emptied by suction. Electric vacuum aspira-
tion is a safe and effective abortion method.   
Endometrium– The mucous membrane that
lines the inside of the uterus. 
Evidence-based medicine– The process of
systematically finding, appraising, and using
contemporaneous research findings as the
basis for clinical decisions.
FDA– see United States Food and Drug
Administration.
FDA-approved– Pre-marketing approval of
new drugs and certain medical devices
required by the FDA. Labels accompanying
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the products list only those uses approved
by the FDA, and authorized marketing by
manufacturers is limited to those uses.
However, the FDA does not have the author-
ity to control how doctors use the products
once they pass the agency’s initial review.
Physicians may–and frequently do–pre-
scribe drugs or use devices in ways not
included on the FDA-approved label (see
Off-label use). 
Folex®– One of the brand names of
methotrexate (see Methotrexate).
Informed consent– Except in the case of an
emergency, a doctor must obtain a patient’s
agreement (informed consent) to any course
of treatment. Doctors are required to tell the
patient anything that would substantially
affect the patient’s decision. Such informa-
tion typically includes the nature and pur-
pose of the treatment, its risks and conse-
quences and alternative courses of treatment. 
Last Menstrual Period (LMP)– The number
of days or weeks from the first day of the
last menstrual period. This number is used
by medical professionals to calculate the
gestational age of the embryo or fetus.
Manual Vacuum Aspiration (MVA)– A sur-
gical abortion method performed with a
handheld syringe as a source of suction for
removing uterine contents. MVA may be per-
formed in settings such as doctors’ offices,
clinics and emergency rooms that lack elec-
tric surgical abortion equipment. MVA is as
safe and effective as electric vacuum aspira-
tion.
Medical abortion– The termination of early
pregnancy using a drug or combination of
drugs that are usually administered orally,
intramuscularly and/or vaginally, first caus-
ing the pregnancy to terminate and then
causing the uterus to expel the products of
conception.  
Methotrexate– A drug used for medical
abortion (usually in combination with miso-
prostol) which stops cell division in the
developing placenta, thereby interfering
with cell growth and further attachment to
the uterine lining.  
Mifeprex™– The brand name of mifepris-
tone in the U.S. Mifepristone is also known
as RU-486 (see Mifepristone and RU- 486).
Mifepristone– A drug used for medical abor-
tion (usually in combination with misopros-
tol) which alters the uterine lining and dis-
rupts attachment of a fertilized egg.
Mifepristone is approved by the FDA for
medical abortion.
Misopristol– A drug used in combination
with mifepristone or methotrexate for med-
ical abortion. Misoprostol softens the cervix
and stimulates uterine contractions to expel
the products of conception. 
Off-label use– The practice of prescribing a
drug for a disease or a condition other than
the indication for which it was approved by
the FDA. Off-label use is an integral feature
of medical practice and often reflects
approaches that have been extensively
reported in medical literature. A substantial
body of medical and scientific literature has
developed around off-label uses, including
articles in peer-reviewed professional jour-
nals, references in medical textbooks, and
discussions and workshops at medical sym-
posia. The American Medical Association
estimates that 40-60% of prescriptions are
written for off-label uses. The FDA generally
bars pharmaceutical and device manufactur-
ers from communicating with physicians
and other health care professionals about
off- label uses. 
Refusal clauses– State legislation, also
known as “conscience clauses,” explicitly
allowing some health care professionals or
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institutions, often on religious or moral
grounds, to refuse to provide or participate
in some types of reproductive health care,
such as abortion, contraceptive or steriliza-
tion services.
RU-486– The chemical compound name for
mifepristone which was originally devel-
oped by the French pharmaceutical compa-
ny, Rousell-Uclaf (see Mifepristone and
Mifeprex).
Spontaneous abortion– The loss of a fetus
during pregnancy due to natural causes; a
miscarriage is the spontaneous termination
of a pregnancy before the fetus has reached
20 weeks.
Subpart H– An FDA rule which allows for
the regulation of new drugs and expedited
review of drugs for serious or life-threaten-
ing illnesses. According to the FDA,
Mifepristone was approved under Subpart H
in order to place safety restrictions on its
distribution. The approval of mifepristone
was not expedited. The FDA approved
mifepristone only after reviewing three com-
plete phases of clinical trials, which is the
standard review process. Approval for
mifepristone was issued more than four
years after the sponsor (Danco Laboratories)
submitted its application. 
Surgical back-up– In the case of medical
abortion, refers to arrangements made by a
provider for a patient to receive a surgical
abortion in the event of an incomplete med-
ical abortion or ongoing pregnancy. 
Ultrasound–a type of imaging which uses
high frequency sound waves; used in deter-
mining the gestational age of a pregnancy.
United States Food and Drug
Administration (FDA)– An agency of the
Department of Health and Human Services
responsible for enforcing laws enacted by
Congress which deal with the regulation of
food (excluding meat, poultry and some egg
products), drugs, medical devices, blood,
biological products (such as vaccines and
tissues for transplantation) and cosmetics.
The FDA also monitors the safety of the
nation’s food supply, reviews scientific evi-
dence related to new drugs or medical
devices and investigates the safety of com-
monly used chemicals. 
G L O S S A R Y  47
G
lo
ss
ar
y
R E S O U R C E S 49
The Abortion Access Project
552 Massachusetts Avenue, Suite 215
Cambridge, MA 02139
(617) 661-1161
www.abortionaccess.org
The Alan Guttmacher Institute
120 Wall Street, 21st Floor
New York, NY 10005
(212) 248-1111
www.agi-usa.org
American Civil Liberties Union (ACLU)
Reproductive Freedom Project
125 Broad Street, 18th Floor
New York, NY 10004
www.aclu.org/issues/reproduct/hmrr.html
American College of Nurse Midwives
818 Connecticut Avenue, NW, Suite 900
Washington, DC 20006
(202) 728-9860
www.midwife.org
American College of Obstetricians and
Gynecologists
409 12th Street, SW
P.O. Box 96920
Washington, DC 20090-6920
(202) 638-5577
www.acog.org
American Medical Women’s Association
801 North Fairfax Street, Suite 400
Alexandria, VA 22314-1767
(703) 838-0500
www.amwa-doc.org
American Public Health Association
800 I Street, NW
Washington, DC 20001
(202) 777-2742
www.apha.org
Association of Reproductive 
Health Professionals
2401 Pennsylvania Avenue, NW, Suite 350
Washington, DC 20037-1718
(202) 466-3825
www.arhp.org
Center for Reproductive 
Health Research & Policy
UCSF, 3333 California Street
Suite 335, Box 0744
San Francisco, CA 94143-0744
(415) 502-4098
http://reprohealth.ucsf.edu
Center for Reproductive Law and Policy
120 Wall Street, 14th Floor
New York, NY 10005
(917) 637-3600
www.crlp.org
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Clinicians for Choice
c/o The National Abortion Federation
1755 Massachusetts Avenue, NW, Suite 600
Washington, DC 20036
(202) 667-5881
www.cliniciansforchoice.org
Danco Laboratories, LLC (maker of MifepreTM)
(877) 432-7596
www.earlyoptionpill.com
Henry J. Kaiser Family Foundation
2400 Sand Hill Road 
Menlo Park, CA 94025 
(650) 854-9400 
www.kff.org
Ipas
300 Market Street, Suite 200
Chapel Hill, NC 27516
(919) 967-7052, (800) 334-8446
www.ipas.org
Medical Students for Choice
2041 Bancroft Way, Suite 201
Berkeley, CA 94704
(510) 540-1195
www.ms4c.org
National Abortion and Reproductive Rights
Action League
1156 15th Street, NW, Suite 700
Washington, DC 20005
(202) 973-3000
www.naral.org
National Abortion Federation
1755 Massachusetts Avenue, NW, Suite 600
Washington, DC 20036
(202) 667-5881
www.prochoice.org
National Women’s Health Network
514 10th Street, NW, Suite 400
Washington, DC 20004
(202) 347-1140
www.womenshealthnetwork.org
National Women’s Law Center
11 Dupont Circle, NW, Suite 800
Washington, DC 20036
(202) 588-5180
www.nwlc.org
Physicians for Reproductive Choice 
and Health
55 West 39th Street, 10th Floor
New York, NY 10018
(646) 366-1890
www.prch.org
Planned Parenthood Federation of America
810 Seventh Avenue
New York, MY 10019
(212) 541-7800, (800) 230-PLAN
www.plannedparenthood.org
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